The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida

A large number of studies have been published over the last two decades examining molecular mechanisms of antifungal resistance in Candida species. However, few of these studies have explored how such mechanisms influence the host immune response to this opportunistic pathogen. With recent advances in our understanding of host immunity to Candida, a body of emerging literature has begun to explore how intrinsic and adaptive resistance mechanisms in Candida alter host immune system evasion and detection, which could have important implications for understanding (1) why certain resistance mechanisms and Candida species predominate in certain patient populations, (2) the biological context for understanding why high in vitro levels of resistance in may not necessarily correlate with risk of drug failure in vivo and (3) insight into effective immunotherapeutic strategies for combatting Candida resistance. Although this area of research is still in its infancy, two themes are emerging: First, the immunoevasion and intracellular persistence of C. glabrata may be a key factor in the capability of this species to persist in the course of multiple antifungal treatments and develop multidrug resistance. Second, changes in the cell wall associated with antifungal resistance often favor evasion for the host immune response.

[1]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.

[2]  N. Wiederhold Paradoxical echinocandin activity: a limited in vitro phenomenon? , 2009, Medical mycology.

[3]  B. Wickes,et al.  Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. , 2002, The Journal of antimicrobial chemotherapy.

[4]  D. Kontoyiannis,et al.  Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies , 2008, Antimicrobial Agents and Chemotherapy.

[5]  M. Jacobsen,et al.  Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection , 2010, Antimicrobial Agents and Chemotherapy.

[6]  B. Hube,et al.  Interaction of pathogenic yeasts with phagocytes: survival, persistence and escape. , 2010, Current opinion in microbiology.

[7]  D. Andes,et al.  Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene , 2010, Antimicrobial Agents and Chemotherapy.

[8]  Russell E. Lewis,et al.  Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences , 2007, Antimicrobial Agents and Chemotherapy.

[9]  B. Posteraro,et al.  Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice , 2011, Antimicrobial Agents and Chemotherapy.

[10]  G. Fadda,et al.  Role of AFR1, an ABC Transporter-Encoding Gene, in the In Vivo Response to Fluconazole and Virulence of Cryptococcus neoformans , 2006, Infection and Immunity.

[11]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Bopp,et al.  Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. , 2006, Journal of medical microbiology.

[13]  Ronald N. Jones,et al.  Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). , 2010, Diagnostic microbiology and infectious disease.

[14]  Y. Okawa,et al.  Significant differences in the cell‐wall mannans from three Candida glabrata strains correlate with antifungal drug sensitivity , 2012, The FEBS journal.

[15]  D. Lawrence,et al.  Effects of echinocandins on cytokine/chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide. , 2012, Diagnostic microbiology and infectious disease.

[16]  E. Anaissie,et al.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  L. Bopp,et al.  Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. , 2008, The Journal of antimicrobial chemotherapy.

[18]  T. C. White,et al.  Studies of the paradoxical effect of caspofungin at high drug concentrations. , 2005, Diagnostic microbiology and infectious disease.

[19]  D. Kontoyiannis,et al.  Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. , 2008, Medical mycology.

[20]  S. Kelly,et al.  Azole Resistance by Loss of Function of the Sterol Δ5,6-Desaturase Gene (ERG3) in Candida albicans Does Not Necessarily Decrease Virulence , 2012, Antimicrobial Agents and Chemotherapy.

[21]  D. Denning Echinocandin antifungal drugs , 2003, The Lancet.

[22]  D. Kontoyiannis,et al.  Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. , 2011, The Journal of infectious diseases.

[23]  D. Andes,et al.  Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. , 2007, Antimicrobial agents and chemotherapy.

[24]  D. Marriott,et al.  Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  S. Smeekens,et al.  The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis , 2011, European journal of immunology.

[26]  K. Bartizal,et al.  Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies , 1996, Infection and immunity.

[27]  J. Graybill,et al.  Fluconazole versus Candida albicans: A Complex Relationship , 1998, Antimicrobial Agents and Chemotherapy.

[28]  D. Stevens,et al.  Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for β-1,6-Glucan Synthesis Inhibition by Caspofungin , 2006, Antimicrobial Agents and Chemotherapy.

[29]  M. Netea,et al.  An integrated model of the recognition of Candida albicans by the innate immune system , 2008, Nature Reviews Microbiology.

[30]  G. Kardos,et al.  In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin , 2010, The Journal of Microbiology.

[31]  M. Borg-von Zepelin,et al.  Difference in virulence between fluconazole‐susceptible and fluconazole‐resistant Candida albicans in a mouse model , 2011, Mycoses.

[32]  K. Kuchler,et al.  The Facultative Intracellular Pathogen Candida glabrata Subverts Macrophage Cytokine Production and Phagolysosome Maturation , 2011, The Journal of Immunology.

[33]  C. Munro,et al.  Fungal echinocandin resistance , 2010, F1000 biology reports.

[34]  N. Gow,et al.  Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo , 2011, Antimicrobial Agents and Chemotherapy.

[35]  L. Romani Immunity to fungal infections , 2004, Nature Reviews Immunology.

[36]  M. Zupancic,et al.  A yeast by any other name: Candida glabrata and its interaction with the host. , 2005, Current opinion in microbiology.

[37]  C. Clancy,et al.  Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum , 2011, Antimicrobial Agents and Chemotherapy.

[38]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[39]  G. Fadda,et al.  Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence , 2009, PLoS pathogens.

[40]  N. Gow,et al.  Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins , 2008, PLoS pathogens.

[41]  J. Latgé,et al.  Sensing of mammalian IL-17A regulates fungal adaptation and virulence , 2012, Nature Communications.

[42]  M. Netea,et al.  The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. , 2002, The Journal of infectious diseases.

[43]  R. Homayouni,et al.  Genome-Wide Expression Profiling of the Response to Azole, Polyene, Echinocandin, and Pyrimidine Antifungal Agents in Candida albicans , 2005, Antimicrobial Agents and Chemotherapy.

[44]  K. Kuchler,et al.  Candida glabrata Persistence in Mice Does Not Depend on Host Immunosuppression and Is Unaffected by Fungal Amino Acid Auxotrophy , 2009, Infection and Immunity.

[45]  Russell E. Lewis,et al.  Attenuation of the Activity of Caspofungin at High Concentrations against Candida albicans: Possible Role of Cell Wall Integrity and Calcineurin Pathways , 2005, Antimicrobial Agents and Chemotherapy.

[46]  B. Maras,et al.  Identification of Major Glucan-Associated Cell Wall Proteins of Candida albicans and Their Role in Fluconazole Resistance , 2002, Antimicrobial Agents and Chemotherapy.

[47]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[48]  D. Andes,et al.  Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[49]  T. Patterson,et al.  Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans , 2011, Antimicrobial Agents and Chemotherapy.

[50]  James B. Anderson Evolution of antifungal-drug resistance: mechanisms and pathogen fitness , 2005, Nature Reviews Microbiology.

[51]  R. Filmon,et al.  In-vivo selection of an azole-resistant petite mutant of Candida glabrata. , 2000, Journal of medical microbiology.

[52]  D. Perlin Antifungal drug resistance: do molecular methods provide a way forward? , 2009, Current opinion in infectious diseases.

[53]  G. Fink,et al.  A Drug-Sensitive Genetic Network Masks Fungi from the Immune System , 2006, PLoS pathogens.

[54]  Duccio Cavalieri,et al.  The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans , 2011, Journal of leukocyte biology.

[55]  D. MacCallum Hosting Infection: Experimental Models to Assay Candida Virulence , 2011, International journal of microbiology.

[56]  M. Laverdière,et al.  Inactivation of Sterol Δ5,6-Desaturase Attenuates Virulence in Candida albicans , 2005, Antimicrobial Agents and Chemotherapy.

[57]  Alistair J. P. Brown,et al.  Candida albicans morphogenesis and host defence: discriminating invasion from colonization , 2011, Nature Reviews Microbiology.

[58]  Steven D. Brown,et al.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[59]  M. Laverdière,et al.  Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans. , 2005, Antimicrobial agents and chemotherapy.

[60]  L. Bopp,et al.  Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. , 2005, Diagnostic microbiology and infectious disease.

[61]  A. Rodloff,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion , 2010, Journal of Clinical Microbiology.

[62]  E. Katchburian,et al.  Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four Different Candida Species , 2010, Antimicrobial Agents and Chemotherapy.

[63]  Gerald R. Fink,et al.  Dynamic, Morphotype-Specific Candida albicans β-Glucan Exposure during Infection and Drug Treatment , 2008, PLoS pathogens.

[64]  D. Sanglard,et al.  Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata , 2001, Antimicrobial Agents and Chemotherapy.

[65]  D. Perlin Current perspectives on echinocandin class drugs. , 2011, Future microbiology.

[66]  E. Anaissie,et al.  Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  M. Netea,et al.  Toll-Like Receptor 2 Suppresses Immunity against Candida albicans through Induction of IL-10 and Regulatory T Cells , 2004, The Journal of Immunology.

[68]  L. Cowen,et al.  Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms , 2011, PLoS pathogens.

[69]  Alexander D. Johnson,et al.  A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans , 2012, Cell.

[70]  M. Motyl,et al.  Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome , 2005, Antimicrobial Agents and Chemotherapy.

[71]  D. Kontoyiannis,et al.  Resistance to echinocandins comes at a cost , 2012, Virulence.

[72]  M. Castanheira,et al.  Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata , 2012, Journal of Clinical Microbiology.

[73]  M. Netea,et al.  Recognition of fungal pathogens by Toll-like receptors , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[74]  M. Netea,et al.  Toll‐like receptors and the host defense against microbial pathogens: bringing specificity to the innate‐immune system , 2004, Journal of leukocyte biology.

[75]  David W Williams,et al.  Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. , 2009, Medical mycology.

[76]  M. Pfaller,et al.  Epidemiology of Invasive Mycoses in North America , 2010, Critical reviews in microbiology.

[77]  M. Netea,et al.  Innate immune mechanisms for recognition and uptake of Candida species. , 2010, Trends in immunology.

[78]  C. Hennequin,et al.  Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.

[79]  M. Ghannoum,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution , 2012, Journal of Clinical Microbiology.